Title : An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.

Pub. Date : 2022 May

PMID : 35419627






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Inhibition of AKT further increased the response of tumor cells to Olaparib in a PDX model derived from a recurrent platinum-resistant ovarian cancer patient. olaparib AKT serine/threonine kinase 1 Homo sapiens
2 Interestingly, mechanism study revealed that AKT inhibition decreased PARP enzyme activity as measured by PAR level and/or reduced PARP1 protein level in the tumor cell lines and PDX tumor tissues, which may explain the observed combined anti-tumor effect of LAE003 and Olaparib. olaparib AKT serine/threonine kinase 1 Homo sapiens